AU2008246195B2 - Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates - Google Patents

Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates Download PDF

Info

Publication number
AU2008246195B2
AU2008246195B2 AU2008246195A AU2008246195A AU2008246195B2 AU 2008246195 B2 AU2008246195 B2 AU 2008246195B2 AU 2008246195 A AU2008246195 A AU 2008246195A AU 2008246195 A AU2008246195 A AU 2008246195A AU 2008246195 B2 AU2008246195 B2 AU 2008246195B2
Authority
AU
Australia
Prior art keywords
virus
immunodeficient subject
compound
subject
immunodeficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008246195A
Other languages
English (en)
Other versions
AU2008246195A1 (en
Inventor
George R. Painter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biodefence Operations Lansing LLC
Original Assignee
Emergent Biodefence Operations Lansing LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biodefence Operations Lansing LLC filed Critical Emergent Biodefence Operations Lansing LLC
Publication of AU2008246195A1 publication Critical patent/AU2008246195A1/en
Application granted granted Critical
Publication of AU2008246195B2 publication Critical patent/AU2008246195B2/en
Assigned to EMERGENT BIODEFENCE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENCE OPERATIONS LANSING LLC Request for Assignment Assignors: CHIMERIX, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008246195A 2007-04-27 2008-04-25 Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates Active AU2008246195B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91453207P 2007-04-27 2007-04-27
US60/914,532 2007-04-27
PCT/US2008/005322 WO2008133966A1 (en) 2007-04-27 2008-04-25 Methods of reducing nephrotoxicity in subjects administered with nucleoside

Publications (2)

Publication Number Publication Date
AU2008246195A1 AU2008246195A1 (en) 2008-11-06
AU2008246195B2 true AU2008246195B2 (en) 2014-06-05

Family

ID=39523817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008246195A Active AU2008246195B2 (en) 2007-04-27 2008-04-25 Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates

Country Status (9)

Country Link
US (2) US20120010170A1 (cg-RX-API-DMAC7.html)
EP (1) EP2155257B1 (cg-RX-API-DMAC7.html)
JP (2) JP2010525063A (cg-RX-API-DMAC7.html)
CN (2) CN101678122A (cg-RX-API-DMAC7.html)
AU (1) AU2008246195B2 (cg-RX-API-DMAC7.html)
CA (1) CA2685285A1 (cg-RX-API-DMAC7.html)
ES (1) ES2609095T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009011573A (cg-RX-API-DMAC7.html)
WO (1) WO2008133966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CN102665729A (zh) * 2009-10-30 2012-09-12 奇默里克斯公司 用于治疗病毒相关性疾病的方法
AU2010313273B2 (en) * 2009-10-30 2015-04-02 Emergent Biodefense Operations Lansing Llc Methods of treating viral associated diseases
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
CN105998039A (zh) * 2010-08-31 2016-10-12 奇默里克斯公司 膦酸酯衍生物及其合成方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US20140011769A1 (en) * 2012-07-03 2014-01-09 Chimerix, Inc. Methods of Treating Retroviral Infections and Related Dosage Regimes
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
UA116825C2 (uk) 2013-11-15 2018-05-10 Чимерикс Інк. Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
AU2017290703B2 (en) * 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019232A1 (en) * 1999-12-03 2004-01-29 Hostetler Karl Y. Phosphonate compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050048539A (ko) * 2001-10-06 2005-05-24 메리얼엘엘씨 CpG 제제 및 관련된 방법
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019232A1 (en) * 1999-12-03 2004-01-29 Hostetler Karl Y. Phosphonate compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIDANSET D. J. et al.: The Journal Of Infectious Diseases, vol. 190, no. 3, 1 August 2004, pages 499-503 *
HELD, T. K. et al: Bone Marrow Transplantation, Nature Publishing Group, GB, vol. 26, no. 3, 1 January 2000, pages 347-350 *
HOSTETLER K.Y. et al.: Global Antiviral Journal, vol. 2, no. 2, 2006 , pages 96-97 *
HOSTETLER, K. Y. et al: Antimicrobial Agents And Chemotherapy, American Society For Microbiology, Washington, DC, vol. 50, no. 8, 1 August 2006, pages 2857-2859 *
PAINTER G. R. et al: Trends In Biotechnology, Elsevier Publications, Cambridge, GB, vol. 22, no. 8, 1 August 2004, pages 423-427 *

Also Published As

Publication number Publication date
JP2015063538A (ja) 2015-04-09
ES2609095T3 (es) 2017-04-18
CN102702260A (zh) 2012-10-03
MX2009011573A (es) 2010-01-20
WO2008133966A1 (en) 2008-11-06
CA2685285A1 (en) 2008-11-06
EP2155257A1 (en) 2010-02-24
CN101678122A (zh) 2010-03-24
JP2010525063A (ja) 2010-07-22
US20160303147A1 (en) 2016-10-20
AU2008246195A1 (en) 2008-11-06
US20120010170A1 (en) 2012-01-12
EP2155257B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
EP2155257B1 (en) Methods of reducing nephrotoxicity in subjects administered with nucleoside
US7034014B2 (en) Phosphonate compounds
US7652001B2 (en) Pharmacologically active agents containing esterified phosphonates and methods for use thereof
EP1914237A2 (en) Phosphonate ester antiviral compounds
HK1114858B (en) Phosphonate ester antiviral compounds
HK1114858A (en) Phosphonate ester antiviral compounds
ZA200204194B (en) Phosphonate compounds.

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EMERGENT BIODEFENCE OPERATIONS LANSING LLC

Free format text: FORMER OWNER(S): CHIMERIX, INC.